QuatRx Anticipates NDA Filing For Vaginal Atrophy Therapy Ophena In 2009/2010
This article was originally published in The Pink Sheet Daily
Executive Summary
The non-estrogen treatment for postmenopausal women is a potential blockbuster, CEO Zerbe tells “The Pink Sheet” DAILY.